Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib + penpulimab + chemotherapy as first-line treatment for extensive-stage small cell lung cancer
ChiCTR2200065238Phase 2Recruiting
- Sponsor
- The Third People's Hospital of Zhengzhou
- Start
- Nov 2022
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib and penpulimab in small cell lung cancer (SCLC), sponsored by The Third People's Hospital of Zhengzhou. Primary endpoint: Progression-free survival. Started Nov 2022; status: recruiting.
02
Drugs
anlotinibpenpulimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2200065238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200065238.